MSTN and hepatocellular carcinoma: Predictive performance of serum myostatin levels for development of HCC was higher in male patients than that in female patients: Time-dependent AUROC of serum myostatin levels for development of HCC within 5 years was 0.77 (95% CI 0.74–0.80) in male patients (n = 895) and 0.62 (95% CI 0.55–0.69) in female patients (n = 182).